Stay up to date with the latest research, tips, and trends in fitness, nutrition, and weight management.
Why does the gut microbiome lose its balance as we age? Researchers at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena now present a new explanation in a paper published in "PLoS Biology".
Better heart health before the pandemic was linked to a lower risk of severe COVID-19 events, according to research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.
Smaller plastic particles have more effects on neurons, the key information processing cells of the brain, new research from the University of Eastern Finland shows.
"Transmissible prion is extremely stable and very hard to destroy with chemical disinfectants or heat — far more so than for the case of viruses and bacteria," writes Dr. William Brown.
Researchers investigate the link between estrogen loss and Alzheimer's disease using genetically engineered mouse models.
Here are the latest biotech updates, including a new brain organoid assay and an epigenomics research advancement.
Approaching retirement requires a mindset shift to find new meaning. Learn how hobbies, volunteering, and social connections enhance well-being and purpose.
Hellyer first noticed reduced strength in his left thumb, which gradually worsened over more than a decade.
Occupational exposure and residential exposure to coal operations are associated with worse cancer mortality, according to a review published in Public Health.
COVID-19 continues to cause substantial illness, particularly among older adults and individuals with underlying conditions. Updated vaccines are designed to better protect against the strains of the virus that are currently circulating. However, real-world evidence on the effectiveness of updated vaccines remains limited. Here we show the early vaccine effectiveness (VE) of the BNT162b2 LP.8.1-adapted COVID-19 vaccine against mild-to-moderate COVID-19 outcomes. We used a test-negative case-control design to estimate early VE of the BNT162b2 LP.8.1-adapted vaccine against COVID-19 emergency department/urgent care (ED/UC) and outpatient visits. Adult patients from the US Veterans Affairs Healthcare System with an acute respiratory infection (ARI) who underwent SARS-CoV-2 testing from September 10 to November 30, 2025, were included. VE was estimated using multivariable logistic regression adjusted for patient demographics and clinical characteristics. Among 34,455 ARI episodes, 10.7% were COVID-19 cases. A total of 1.2% of cases and 2.6% of controls received the BNT162b2 LP.8.1 vaccine, with a median time since vaccination of 29 days (interquartile range 20-–41). BNT162b2 LP.8.1 vaccine was effective during the early 2025–2026 respiratory virus season. VE was 57% (95% confidence interval [CI] 39–70%) against ED/UC visits and 54% (95% CI 15–75%) against outpatient visits. These findings inform shared decision-making in clinical practice and support the continued importance of COVID-19 vaccination in populations for whom it is recommended. This study estimates early vaccine effectiveness (VE) of the BNT162b2 LP.8.1-adapted vaccine against COVID-19 in adult patients from the United States Veterans Affairs Healthcare System with an acute respiratory infection (ARI).